Primary Care Guidelines podcast

Podcast - NICE News - October 2026

0:00
8:45
Spol 15 sekunder tilbage
Spol 15 sekunder frem

The video version of this podcast can be found here:

·       https://youtu.be/8Fnx4matnfk

This episode makes reference to guidelines produced by the "National Institute for Health and Care Excellence" in the UK, also referred to as "NICE". The content on this channel reflects my professional interpretation/summary of the guidance and I am in no way affiliated with, employed by or funded/sponsored by NICE.

NICE stands for "National Institute for Health and Care Excellence" and is an independent organization within the UK healthcare system that produces evidence-based guidelines and recommendations to help healthcare professionals deliver the best possible care to patients, particularly within the NHS (National Health Service) by assessing new health technologies and treatments and determining their cost-effectiveness; essentially guiding best practices for patient care across the country.

My name is Fernando Florido and I am a General Practitioner in the United Kingdom. In this episode I go through new and updated recommendations published in September 2026 by the National Institute for Health and Care Excellence (NICE), focusing on those that are relevant to Primary Care only.

 

I am not giving medical advice; this video is intended for health care professionals, it is only my summary and my interpretation of the guidelines and you must use your clinical judgement.  

 

Disclaimer:

The Video Content on this channel is for educational purposes and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read or seen on this YouTube channel. The statements made throughout this video are not to be used or relied on to diagnose, treat, cure or prevent health conditions.

In addition, transmission of this Content is not intended to create, and receipt by you does not constitute, a physician-patient relationship with Dr Fernando Florido, his employees, agents, independent contractors, or anyone acting on behalf of Dr Fernando Florido.

Intro / outro music: Track: Halfway Through — Broke In Summer [Audio Library Release] 

 

There is a podcast version of this and other videos that you can access here:

 

Primary Care guidelines podcast:

 

·       Redcircle: https://redcircle.com/shows/primary-care-guidelines

·       Spotify: https://open.spotify.com/show/5BmqS0Ol16oQ7Kr1WYzupK

·       Apple podcasts: https://podcasts.apple.com/gb/podcast/primary-care-guidelines/id1608821148


There is a YouTube version of this and other videos that you can access here: 

  • The Practical GP YouTube Channel: 

https://youtube.com/@practicalgp?si=ecJGF5QCuMLQ6hrk


The Full NICE News bulletin for October 2026 can be found here:

 

·       https://www.nice.org.uk/guidance/published?from=2026-10-01&to=2026-10-31

 

The updated HealthTech guidance on Virtual reality technologies for treating agoraphobia or agoraphobic avoidance: early value assessment [HTG701] can be found here:

·       https://www.nice.org.uk/guidance/htg701

The updated HealthTech guidance on Digital technologies for managing non-specific low back pain: early value assessment [HTG712] can be found here:

·       https://www.nice.org.uk/guidance/htg712

The updated HealthTech guidance on Digitally enabled therapies for adults with anxiety disorders: early value assessment [HTG676] can be found here:

·       https://www.nice.org.uk/guidance/htg676

The NICE Technology appraisal on Insulin efsitora alfa for treating type 2 diabetes [TA1200] can be found here:

·       https://www.nice.org.uk/guidance/ta1200

Transcript

If you are listening to this podcast on YouTube, for a better experience, switch to the video version. The link is in the episode description.

Hello and welcome. I’m Fernando, a GP in the UK. In today’s episode, we’ll look at the NICE updates published in October 2026, focusing on what is relevant in Primary Care only.

This month, we have three areas to cover: a new once-weekly insulin for type 2 diabetes, digital technologies for managing low back pain, and digital treatments for certain mental health conditions.

Right, let’s jump into it.

Let's start with the new NICE technology appraisal on insulin efsitora alfa, also known as Onswik, for treating type 2 diabetes in adults.

So, what is insulin efsitora alfa?

It is a genetically engineered, ultra-long-acting basal insulin that works in a similar way to other basal insulins, but with one important difference: it is administered by subcutaneous injection once a week rather than once or twice a day.

It is designed to provide relatively stable glucose control throughout the week.

But how does a once-weekly insulin actually work?

What makes efsitora interesting is that it is not simply conventional insulin formulated to be absorbed more slowly. Instead, its molecular structure has been modified to allow it to remain in the circulation for much longer.

Like other insulins, efsitora binds to insulin receptors, with glucose-lowering mechanisms that are essentially the same as those of human insulin. The main difference is its pharmacokinetics, particularly how slowly it is cleared from the circulation.

Now, let's look at the NICE recommendations.

NICE recommends insulin efsitora alfa as an option for adults with type 2 diabetes who need basal insulin treatment.

However, NICE says we should choose the least expensive suitable option, taking into account the benefits and disadvantages of the available insulins, administration costs and patient preferences.

So, what are the potential advantages?

Once-weekly injections may be particularly helpful for patients who need assistance with insulin administration, such as frail patients, people with learning disabilities, or those with visual, cognitive or dexterity problems.

They may also benefit people who find daily injections difficult to manage, for example, those of working age.

In terms of effectiveness, clinical trials showed that insulin efsitora alfa provides similar control to once-daily basal insulins.

NICE also found that overall costs could be similar or lower, particularly when fewer injections reduce the need for nursing support.

So, what does this mean for us in primary care?

This gives us another basal insulin option for adults with type 2 diabetes, particularly when daily injections are difficult or require additional support.

However, it does not mean that everyone taking daily basal insulin should be switched to a once-weekly preparation.

Treatment should remain individualised, taking into account local prescribing arrangements.

There are also some important practical considerations.

First, dose titration is slower.

Because efsitora remains in the circulation for so long, the full effect of a dose adjustment may take several weeks to become apparent, potentially around four weeks. We should therefore avoid making overly aggressive adjustments based on just a few high glucose readings.

Second, hypoglycaemia remains an important risk, and the prolonged action of efsitora means that the effects of an excessive dose may persist for longer.

And third, we need to be particularly careful about medication errors, as a once-weekly insulin could be confused with daily insulin preparations.

Finally, you may have heard of another once-weekly insulin, insulin icodec.

Both provide prolonged basal insulin activity, but their molecular designs differ, so they achieve their long duration of action through different mechanisms.

Let’s now look at some NICE Health Tech guidance.

The first one is the updated NICE HealthTech guidance on digital technologies for managing non-specific low back pain.

This update extends the evidence generation period until March 2028, to allow for more evidence to be presented.

So, what are these digital technologies?

They are digital programmes that provide support for managing low back pain, including education, exercise programmes and advice on self-management.

NICE recommends four technologies that can be used in the NHS while further evidence is collected, although, they must have appropriate regulatory approval and meet NHS England's standards.

So, why does NICE recommend these technologies?

The available evidence suggests that they may reduce pain, improve everyday functioning and provide more flexible access to treatment.

They could also reduce waiting lists, physiotherapy referrals and GP appointments.

For us in primary care, these technologies may offer another option to support patients with non-specific low back pain. However, availability will depend on local NHS pathways, and we should remember that digital treatment may not be suitable for everyone, particularly people with limited internet access or difficulties using digital technology.

Otherwise, we should also continue to follow the usual NICE recommendations for managing low back pain, including identifying red flags, encouraging physical activity and supporting self-management.

Let’s now look at the other two updated NICE HealthTech guidelines on digital treatments, which are for mental health conditions.

Both updates extend the evidence generation period, and the first, and more relevant to primary care, is on digitally enabled therapies for adults with anxiety disorders.

These are structured psychological treatments delivered through digital platforms, allowing patients to work through therapy programmes with support from a trained practitioner or therapist.

NICE recommends five therapies that can be used in NHS Talking Therapies services while further evidence is collected, provided they have the appropriate NHS approval.

The treatments cover conditions including generalised anxiety symptoms, social anxiety disorder, post-traumatic stress disorder and body dysmorphic disorder.

The available evidence suggests that these therapies may reduce anxiety symptoms, offer more flexible access to treatment and require less therapist time, potentially helping to reduce waiting lists.

However, more evidence is needed about their long-term effectiveness, recovery rates, relapse and impact on NHS resources.

For us in primary care, the main message is that these therapies may offer another option for patients who prefer flexible access to psychological treatment.

However, they are not simply self-help apps. They are delivered through NHS Talking Therapies services with professional support and monitoring, and they may not suit everyone.

The second guideline covers virtual reality technology for treating agoraphobia or agoraphobic avoidance.

NICE supports one technology, which uses virtual reality and CBT techniques to help patients gradually confront situations they find frightening, such as leaving home or entering public places.

This recommendation is specifically for adults with psychosis and severe agoraphobic avoidance, and treatment must be supported by a mental health professional. So, this is mainly relevant to specialist mental health services in secondary care.

However, it is useful for us to know that this choice exists when discussing treatment options with relevant patients.

So that is it, a review of the NICE updates relevant to primary care.

We have come to the end of this episode.

Remember that this is not medical advice, but only my summary and interpretation of the guidelines.

You must always use your clinical judgement.

Thank you for listening and goodbye.

Flere episoder fra "Primary Care Guidelines"